A Mexican-made anti-venin that helps children recover from life-threatening reactions to scorpion stings has received U.S. approval, officials said. The U.S. Food and Drug Administration has approved the antidote Anascorp to treat serious reaction to the stings of bark scorpions, common throughout Arizona and considered a major threat to young children, the Arizona Republic reported Thursday. The scorpions' painful stings can cause children to lose muscle control and can lead to breathing difficulties. About 8,000 scorpion stings are reported in Arizona each year, with several hundred serious enough to require medical attention. "This is a great triumph," said Dr. Leslie Boyer, a University of Arizona pediatrician who spearheaded clinical trials of the anti-venin. Mexican company Instituto Bioclon produces Anascorp from the plasma of horses immunized with scorpion venom. The company agreed to open its operations to the FDA's rigorous inspection process to ensure its manufacturing practices meets the agency's standards, Boyer said. The approval of Anascorp is the first time the FDA has approved a drug developed and made in Latin America, she said.
GMT 18:35 2018 Thursday ,11 January
Syrian refugee sets himself ablaze at UN office in LebanonGMT 18:48 2018 Tuesday ,09 January
Novo Nordisk woos Belgian nano-drug makerGMT 17:54 2017 Wednesday ,27 December
Medical evacuations begin from besieged Syria rebel bastionGMT 12:14 2017 Monday ,25 December
MoHAP successfully conducts cochlear implant operationGMT 18:24 2017 Sunday ,24 December
Palestinian conjoined twins arrive in RiyadhGMT 19:05 2017 Monday ,18 December
new! magazine names fitness & food editorGMT 17:03 2017 Wednesday ,29 November
Spain reports case of 'mad cow disease'GMT 14:05 2017 Saturday ,11 November
EU can't agree on new licence for controversial glyphosate weedkillerMaintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Send your comments
Your comment as a visitor